NO872932D0 - Fremgangsmaate for fremstilling av proteiner med faktor-viii-aktivitet. - Google Patents

Fremgangsmaate for fremstilling av proteiner med faktor-viii-aktivitet.

Info

Publication number
NO872932D0
NO872932D0 NO872932A NO872932A NO872932D0 NO 872932 D0 NO872932 D0 NO 872932D0 NO 872932 A NO872932 A NO 872932A NO 872932 A NO872932 A NO 872932A NO 872932 D0 NO872932 D0 NO 872932D0
Authority
NO
Norway
Prior art keywords
factor
procedure
manufacturing
viii activity
activity proteins
Prior art date
Application number
NO872932A
Other languages
English (en)
Other versions
NO872932L (no
Inventor
Albert Johannes Joseph V Ooyen
Peter Michael Andreoli
Jan Aart Van Mourik
Hans Pannekoek
Original Assignee
Gist Brocades Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868617594A external-priority patent/GB8617594D0/en
Priority claimed from GB868630699A external-priority patent/GB8630699D0/en
Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv
Publication of NO872932D0 publication Critical patent/NO872932D0/no
Publication of NO872932L publication Critical patent/NO872932L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO872932A 1986-07-18 1987-07-14 Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika. NO872932L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868617594A GB8617594D0 (en) 1986-07-18 1986-07-18 Preparation of biologically active proteins
GB868630699A GB8630699D0 (en) 1986-12-23 1986-12-23 Preparation of biologically active proteins

Publications (2)

Publication Number Publication Date
NO872932D0 true NO872932D0 (no) 1987-07-14
NO872932L NO872932L (no) 1988-01-19

Family

ID=26291059

Family Applications (1)

Application Number Title Priority Date Filing Date
NO872932A NO872932L (no) 1986-07-18 1987-07-14 Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.

Country Status (9)

Country Link
EP (1) EP0253455A1 (no)
JP (1) JPS63313587A (no)
AU (1) AU620315B2 (no)
DK (1) DK374087A (no)
FI (1) FI873162A (no)
IL (1) IL83192A (no)
NO (1) NO872932L (no)
NZ (1) NZ221119A (no)
PT (1) PT85349B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
AU591671B2 (en) * 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5278066A (en) * 1985-08-09 1994-01-11 Gist-Brocades Nv Molecular cloning and expression of gene encoding lipolytic enzyme
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US5830735A (en) * 1987-03-06 1998-11-03 Gist-Brocades Nv Method for producing lipolytic enzymes using transformed Pseudomonas
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU627150B2 (en) * 1987-06-12 1992-08-20 Immuno Ag Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) * 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
GB2214508A (en) * 1988-01-27 1989-09-06 Bayer Ag Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences.
KR0165550B1 (ko) * 1989-06-29 1999-01-15 마가렛트 에이. 호른 온도, 산 및/또는 알칼리에 대한 안정성이 증가된 변이체 미생물 알파-아밀라아제
JPH05500512A (ja) * 1989-09-14 1993-02-04 バクスター　インターナショナル　インコーポレーテッド 薬学的組成物を製造するための方法および装置
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
CA2276091A1 (en) * 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
US20050079573A1 (en) 1998-12-23 2005-04-14 Danisco A/S Proteins
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
WO2002024926A1 (en) 2000-09-21 2002-03-28 Dsm N.V. Talaromyces xylanases
WO2002046381A2 (en) 2000-12-07 2002-06-13 Dsm N.V. Method for the prevention or reduction of haze in beverages
KR100867059B1 (ko) 2000-12-07 2008-11-04 디에스엠 아이피 어셋츠 비.브이. 카르복시 말단 프롤린 잔기를 갖는 펩티드가 풍부한단백질 가수분해물
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
CN100519729C (zh) 2002-06-07 2009-07-29 Dsmip资产有限公司 防止或降低饮料混浊的改进方法
TWI328612B (en) 2002-07-25 2010-08-11 Dsm Ip Assets Bv Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
CN101316928B (zh) 2005-11-28 2014-12-10 帝斯曼知识产权资产管理有限公司 产生清洁味道的酶制剂
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
AU2008219305B2 (en) 2007-02-20 2013-08-22 Dsm Ip Assets B.V. Novel sialidase
DK2126060T3 (en) 2007-03-22 2017-01-16 Dsm Ip Assets Bv Hitherto unknown lysyl oxidases
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
WO2011101339A2 (en) 2010-02-18 2011-08-25 Dsm Ip Assets B.V. Fermentation broth and filtration filter cake and uses thereof
WO2012007445A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Mutarotase in crystallization
WO2012007446A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Use of a mutarotase in the production of dried powders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78871T1 (de) * 1984-01-12 1992-08-15 Chiron Corp Proteinzusammensetzung mit koagulations-wirkung und verfahren zu ihrer herstellung.
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta

Also Published As

Publication number Publication date
IL83192A0 (en) 1987-12-31
FI873162A0 (fi) 1987-07-17
EP0253455A1 (en) 1988-01-20
IL83192A (en) 1992-11-15
AU7575487A (en) 1988-01-21
NO872932L (no) 1988-01-19
PT85349B (pt) 1990-04-30
JPS63313587A (ja) 1988-12-21
FI873162A (fi) 1988-01-19
DK374087A (da) 1988-01-19
AU620315B2 (en) 1992-02-20
NZ221119A (en) 1990-08-28
DK374087D0 (da) 1987-07-17
PT85349A (en) 1987-08-01

Similar Documents

Publication Publication Date Title
NO872932D0 (no) Fremgangsmaate for fremstilling av proteiner med faktor-viii-aktivitet.
NO171006C (no) Fremgangsmaate for fremstilling av antioksyderende preparater
NO874467D0 (no) Fremgangsmaate for fremstilling av 3-pyrrolidinoler.
NO870409D0 (no) Fremgangsmaate for spaltning av 1-aminoindaner.
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO885002L (no) Fremgangsmaate for fremstilling av sialocylglycerolipider.
NO882730D0 (no) Fremgangsmaate for fremstilling av aminocyklopentyletere.
NO873400D0 (no) Fremgangsmaate for fremstilling av sulfidfri alkalivaeske.
NO872255D0 (no) Fremgangsmaate for dekaffinering av raakaffe.
NO885200L (no) Fremgangsmaate for fremstilling av pro-legemidler.
NO870828D0 (no) Fremgangsmaate for fremstilling av biskarbamater.
NO168941C (no) Fremgangsmaate for fremstilling av mercaptoacylprolin.
NO863769D0 (no) Fremgangsmaate for fremstilling av 4-hydroksy-2-oksopyrrolin-1-yl-acetamid.
NO165395C (no) Fremgangsmaate for fremstilling av n-(sulfonylmetyl)formamider.
NO880345L (no) Fremgangsmaate for fremstilling av alkyl-tert-butyletere.
NO871721D0 (no) Fremgangsmaate for fremstilling av ergolenderivater.
NO864087D0 (no) Fremgangsmaate for fremstilling av aroylthiazoloner.
NO880834D0 (no) Fremgangsmaate for fremstilling av heterocyclyl-2-propyn-1-aminer.
NO893796D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO875253L (no) Fremgangsmaate for fremstilling av methyl-4-okso-5-tetradecynoat.
NO893795D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO872484D0 (no) Fremgangsmaate for fremstilling av immunogent kompleks.
NO900651D0 (no) Fremgangsmaate for fremstilling av 2-benzyl-1-nafthol.
NO890375D0 (no) Fremgangsmaate for fremstilling av heksanitrostilben.
NO880844L (no) Fremgangsmaate for fremstilling av cytotoksiner.